Development of inflammatory bowel disease (IBD) following the use of biologic treatment for rheumatologic diseases: A review of the Food and Drug Administration Adverse Event Reports System (FAERS)

Presentation Notes

Accepted for presentation at Digestive Disease Week, The Brightest Ideas & Breakthroughs in Digestive Health. May 2-5, 2020; canceled due to COVID-19.

Document Type

Abstract

Link to Full Text

 

Share

COinS